Board of Directors

Q-linea’s BoD consist of a combination of entrepreneurs, inventors and industrial experienced persons representing the major owners of the company, and providing active support to the management.

Holdings as of December 28, 2022.

Erika Kjellberg Eriksson

Director since 2012, chairman of the board since 2018

Erika Kjellberg Eriksson has held board assignments and senior positions in pharmaceutical, biotech and medtech companies for more than 25 years. She has extensive experience from working in both listed and unlisted companies and vast board experience.

Born: 1962
Education: B.Sc in economics, Uppsala University (1985).
Other current assignments: Erika Kjellberg Eriksson is CEO of Nexttobe AB, chairman of the board of directors of Linum AB, Brixton Medical AB, Aros Biotech, Lumina Adhesives AB, AllgoHolding AB, Lokon Pharma AB, and Tanea Medical AB, Director of Vivolux AB and Findolon AB.

Holdings in the Company: Erika Kjellberg Eriksson owns 32,000 shares in the Company.

She is independent in relation to the company and its management, but not in relation to major shareholders.

Marianne Hansson

Director since 2018

Marianne Hansson has over 20 years’ experience in life sciences. She most recently served as CEO of Atlas Antibodies AB and prior to that as business development manager at Affibody Medical AB. She is a co-founder of Affibody AB, Atlas Antibodies AB, ScandiBio Therapeutics AB, ScandiEdge Therapeutics AB, Amylonix AB, ProteomEdge AB, A05 Diagnostics AB and Zytox AB.

Born: 1963
Education: Doctor of technology in biochemistry, KTH Royal Institute of Technology (1998); MSc in chemical engineering, Royal Institute of Technology (1989).
Other ongoing assignments: Marianne Hansson is a member of the board of directors of Intervacc AB (publ) and Mariham Consulting AB, CEO of Mariham Consulting AB and external CEO of ScandiBio Therapeutics AB, ScandiEdge, Therapeutics AB, Amylonix AB, ProteomEdge AB, A05 Diagnostics AB and Zytox AB.

Holdings in the Company: Marianne Hansson owns 3,088 shares in the Company through her wholly owned company Mariham Consulting AB.

She is independent in relation to the company and its management and in relation to major shareholders.

Hans Johansson

Director since 2018

Hans Johansson has extensive experience and a broad contact network from his previous roles in the life sciences and diagnostics industry, most recently as vice president, head of Companion Diagnostics at Thermo Fisher’s Speciality Diagnostics Group. His previous positions include vice president global marketing and business development at Thermo Fisher’s Immuno Diagnostics Division, CEO of Pyrosequencing/Personal Chemistry (now Biotage), and head of laboratories at Pharmacia Biotechnology AB.

Born: 1954
Education: MSc in chemical engineering
Other ongoing assignments: Hans Johansson is chairman of the board of directors of Myrtila AB and Doloradix AB, a member of the board of directors of Immunovia AB (publ), and Swelife.

Holdings in the Company: Hans Johansson owns 5,882 shares in the Company.

He is independent in relation to the company and its management and in relation to major shareholders.

Mario Gualano

Director since 2020

Mario Gualano is currently CEO of BBI Group Ltd., he has more than 25 years of commercial, technical and operational experience in the microbiology and diagnostics industry, including 15 years in international leadership roles with Thermo Fisher Scientific. During his time with Thermo Fisher Scientific, he led Thermo Fisher Scientific’s Specialty Diagnostics Group in APAC and, most recently, was the President of the Microbiology division.

Born: 1969
Education: PhD in Microbiology and Immuno-diagnostics and a MBA from Henley Management College.
Other ongoing assignments: CEO of BBI Solutions Ltd

Holdings in the Company: Mario Gualano does not own any shares in the Company.

He is independent in relation to the company and its management and in relation to major shareholders

Mats Nilsson

Director since 2008 (chairman of the board 2008–2013)

Mats Nilsson is a professor of molecular diagnostics, has founded several companies in the biotech industry and is one of the founders of Q-linea. He has extensive board experience and has served on the board of Elos MedTech AB, which is listed on Nasdaq Stockholm.

Born: 1969
Education: Associate professor of molecular medicine, Uppsala University (2003); PhD in medical genetics, Uppsala University (1998); MSc in biology, Uppsala University (1998).
Other ongoing assignments: Mats Nilsson is Scientific Director and professor of biochemistry at the Science for Life Laboratory at Stockholm University. He also serves as member of the board of directors of EMPE Diagnostics AB, Countagen AB, Aplex Bio AB and Biocyclica Holding AB.

Holdings in the Company: Mats Nilsson owns 444,000 shares in the Company. He owns an additional 53,320 shares in the Company through the related company Biocyclia Holding AB.

He is independent in relation to major shareholders, but not in relation to the company and its management.

Nina Korfu-Pedersen

Director since 2022

Nina Korfu-Pedersen is currently Chief Transformation Officer for control & staff functions at SEB where she also has had roles as SEB’s CFO and global manager for Business Support & Operations. She has long experience of leading major change initiatives globally, operationally and strategically in different industries and roles, both in the consulting industry and in line manager roles. She has more than 15 years of experience in international leadership roles.

Born: 1973
Education: Nina holds a master exam from Handelshöyskolen BI (Norway) and a Master of Arts in International Relations from University of Reading (UK).
Other ongoing assignments: Nina Korfu-Pedersen is a member of the Financial Reporting Board.

Holdings in the Company: Nina Korfu-Pedersen does not own any shares in the Company.

She is independent in relation to the company and its management and in relation to major shareholders

Per-Olof Wallström

Director since 2018

Per-Olof Wallström has 50 years’ experience in the pharmaceutical and biotech industry and has held senior positions in the Nordic region and Europe at companies including Merck AB, Astra AB, Pharmacia AB and Bristol-Myers Squibb AB in the Nordics and Europe. He has also served as CEO of Karo Bio AB, Melacure Therapeutics AB and Q-Med AB.

Born: 1949
Education: MSc Pharm, Uppsala University (1972).
Other ongoing assignments: Per-Olof Wallström is chairman of the board of directors of Camurus AB and Camurus Development AB and a member of the board of directors of Nexttobe AB and Arosia Communication AB.

Holdings in the Company: Per-Olof Wallström owns 5,147 shares in the Company.

He is independent in relation to the company and its management but not in relation to major shareholders.